Inventor · disambiguated record
Gordon Parry
Also filed as: PARRY GORDON
12 granted patents·10 pending applications·121 citations·filing 2000–2022
90Inventor score
Files withBAYER SCHERING PHARMA AG6LABORATORY CORP AMERICA HOLDINGS5LAB CORP AMERICA HOLDINGS4SCHERING AG4Bayer Schering Pharma1
Top patents by PatentIndex Score
22 records- 0195US8349574B2Methods of determining patient response by measurement of Her-3LAB CORP AMERICA HOLDINGS·Filed 2010·Granted Jan 8, 2013·42 cites·51 claims
- 0292US7335748B2RG1 antibodies and uses thereofBAYER SCHERING PHARMA AG·Filed 2004·Granted Feb 26, 2008·46 cites·21 claims
- 0388US9766242B2Methods of determining patient response by measurement of HER-3 and P95LABORATORY CORP AMERICA HOLDINGS·Filed 2015·Granted Sep 19, 2017·3 cites·14 claims
- 0485US9110066B2HER-3 antibodies and methods of useLAB CORP AMERICA HOLDINGS·Filed 2012·Granted Aug 18, 2015·4 cites·34 claims
- 0583US6682902B2DNA encoding a novel RG1 polypeptideSCHERING AG·Filed 2000·Granted Jan 27, 2004·16 cites·11 claims
- 0677US7611706B2RG1 antibodies and uses thereofBAYER SCHERING PHARMA AG·Filed 2007·Granted Nov 3, 2009·2 cites·12 claims
- 0777US7608263B2RG1 antibodies and uses thereofBAYER SCHERING PHARMA AG·Filed 2007·Granted Oct 27, 2009·2 cites·10 claims
- 0876US7307154B2DNA encoding a novel RG1 polypeptideBAYER SCHERING PHARMA AG·Filed 2003·Granted Dec 11, 2007·6 cites·5 claims
- 0971US2023062274A1Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer PatientsLABORATORY CORP AMERICA HOLDINGS·Filed 2022·Application pending·0 cites
- 1065US10775382B2Methods of determining patient response by measurement of HER-3LABORATORY CORP AMERICA HOLDINGS·Filed 2017·Granted Sep 15, 2020·0 cites·22 claims
- 1165US2010081795A1Rg1 antibodies and uses thereofBayer Schering Pharma·Filed 2009·Application pending·0 cites
- 1264US7893217B2Isolated human antibodies that bind epitopes on RG1BAYER SCHERING PHARMA AG·Filed 2007·Granted Feb 22, 2011·0 cites·12 claims
- 1364US7887804B2Methods for treating disease-states associated with RG1 using immunoconjugatesBAYER SCHERING PHARMA AG·Filed 2007·Granted Feb 15, 2011·0 cites·9 claims
- 1462US11401344B2Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patientsLABORATORY CORP AMERICA HOLDINGS·Filed 2018·Granted Aug 2, 2022·0 cites·11 claims
- 1560US2014370523A1Methods of Determining Patient Response by Measurement of HER-2 ExpressionLAB CORP AMERICA HOLDINGS·Filed 2014·Application pending·0 cites
- 1658US2017082626A1Methods of Determining Patient Response by Measurement of HER-2 ExpressionLABORATORY CORP AMERICA HOLDINGS·Filed 2016·Application pending·0 cites
- 1755US2004152139A1DNA encoding a novel RG1 polypeptideSCHERING AG·Filed 2003·Application pending·0 cites
- 1855US2024156869A1Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapyT CURE BIOSCIENCE INC·Filed 2022·Application pending·0 cites
- 1951US2004132156A1Modified hepsin molecules having a substitute activation sequence and uses thereofSCHERING AG·Filed 2003·Application pending·0 cites
- 2050US2010233732A1Methods of Determining Patient Response By Measurement of HER-2 ExpressionLAB CORP AMERICA HOLDINGS·Filed 2010·Application pending·0 cites
- 2142US2006188990A1Novel prostate tumor-specific promoterSCHERING AG·Filed 2003·Application pending·0 cites
- 2235US2002009455A1DNA encoding a novel PROST 03 polypeptideFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →